VIVS

distress 5/10 · elevated risk

$0.45-2%today-91% from 52w high

vivosim.ai9 employeesFounded 2007San Diego, CABiotechnology

Revenue

pre-revenue

Liquidity

$15M

Runway

1.6 yrs

Shares 1y

+34%

Price & events

-77.5% over 6M

CatalystRating changeDilutionFinancingdashed = today

-2.2%

-26.2%

-60.2%

-69.6%

-76.3%

-80.8%

-93.6%

-99.5%

-99.7%

All

Overview

Market Cap: $1.57M
Volume: 393.00K
52 Week Range: $0.45 – $4.78
Total Shares: 3.49M
Float Shares: 3.18M
Short %: 3.98%
% Held by Insiders: 11.05%
% Held by Institutions: 5.74%
RVOL: 0.06x
Beta: 1.40

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 2

2025-03-25partnershipFXR314 · Organovo sold its FXR program including lead asset FXR314 to Eli Lilly for $10M upfront and up to $50M in milestones.SEC 8-K
2025-03-25partnershipFXR agonist · Sale of FXR program and related assets to Lilly for $10M upfront plus up to $50M milestones.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 3,494,071 · 1 offerings/1y · 1 PIPEs

2026-07-178-Kprivate_placement
2026-04-038-Kmaterial_agreement
2026-04-02424B4offering
2026-03-31S-1/Ashelf_registration
2026-03-31EFFECTshelf_effective
2026-03-27S-1shelf_registration
2025-04-11424B5offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified